EGFR and non-small cell lung carcinoma: The FDA granted a breakthrough therapy designation for OTB in NSCLC.10 In May 2016, OTB was approved in South Korea under the trade name OlitaTM for management of patients suffering from metastatic or local advanced EGFR T790M mutation-positive NSCLC.10